Triptolide inhibits vascular endothelial growth factor-mediated angiogenesis in human breast cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Triptolide is known to induce tumor cell apoptosis.
• The specific role of triptolide in breast cancer angiogenesis requires further investigation.

Purpose of the Study:

• To investigate the anti-angiogenic function of triptolide in breast cancer.
• To elucidate the molecular mechanisms by which triptolide affects breast cancer angiogenesis.

Main Methods:

• Assessing vascular endothelial growth factor A (VEGFA) expression in breast cancer cell lines (Hs578T, MDAMB231).
• Performing in vitro angiogenesis assays (tube formation, bromodeoxyuridine incorporation) using human umbilical vein endothelial cells.
• Evaluating the in vivo anti-angiogenic effect in a breast cancer xenograft mouse model.
• Analyzing the expression and activation of key signaling molecules including ERK1/2, HIF1-α, and VEGFA via Western blot and immunohistochemistry.

Main Results:

• Triptolide significantly reduced VEGFA expression in breast cancer cells and demonstrated anti-angiogenic effects in vitro.
• In vivo studies showed decreased tumor vascularization (VEGFA, CD31) and proliferation (Ki67) following triptolide treatment.
• Triptolide suppressed extracellular signal-related kinase (ERK)1/2 activation and hypoxia-inducible factor (HIF)1-α expression.
• Overexpression of HIF1-α partially reversed the inhibitory effect of triptolide on VEGFA, confirming its role in the pathway.

Conclusions:

• Triptolide exhibits significant anti-angiogenic properties in breast cancer models.
• The mechanism involves the inhibition of the ERK1/2-HIF1-α-VEGFA signaling axis.
• Triptolide represents a potential therapeutic agent for targeting breast cancer angiogenesis.